Johnson & Johnson (NYSE:JNJ) insider Joaquin Duato sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $144.36, for a total transaction of $5,774,400.00. Following the transaction, the insider now owns 112,848 shares of the company’s stock, valued at $16,290,737.28. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of NYSE JNJ traded up $0.04 during midday trading on Friday, reaching $145.34. 5,343,128 shares of the stock were exchanged, compared to its average volume of 7,921,995. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The company has a market cap of $388.35 billion, a PE ratio of 18.21, a price-to-earnings-growth ratio of 2.26 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. During the same period last year, the company earned $1.90 earnings per share. The company’s quarterly revenue was up 3.6% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post 8.16 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be given a $0.90 dividend. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 annualized dividend and a dividend yield of 2.48%. Johnson & Johnson’s dividend payout ratio is presently 49.32%.

JNJ has been the subject of several recent research reports. Raymond James raised their target price on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Credit Suisse Group raised their target price on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Citigroup raised their target price on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Finally, Wells Fargo & Co restated an “outperform” rating and set a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $142.54.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Selective Wealth Management acquired a new position in Johnson & Johnson during the third quarter valued at approximately $105,000. Financial Gravity Wealth Inc. acquired a new position in Johnson & Johnson during the first quarter valued at approximately $105,000. CSat Investment Advisory L.P. acquired a new position in Johnson & Johnson during the second quarter valued at approximately $107,000. WP Advisors LLC acquired a new position in Johnson & Johnson during the second quarter valued at approximately $108,000. Finally, FNY Investment Advisers LLC acquired a new position in Johnson & Johnson during the second quarter valued at approximately $117,000. 66.60% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Joaquin Duato Sells 40,000 Shares of Johnson & Johnson (JNJ) Stock” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/11/10/joaquin-duato-sells-40000-shares-of-johnson-johnson-jnj-stock.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Leveraged Buyout (LBO) Explained

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.